Trial Profile

Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms ULYSSES
Sponsors Advantagene; Candel Therapeutics

Most Recent Events

13 Jan 2025 According to a Candel Therapeutics media release, company looking to report updated overall survival data for CAN-2409 from phase 2a clinical trial in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025.
30 Mar 2023 According to a Candel Therapeutics media release, topline results are expected in Q4 2024.
22 Feb 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com